US › Healthcare

ImmuCell Corporation (ICCC)

US · Healthcare · Biotechnology

$11.07+0.27%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$10.4M
Revenue YoY
+28.4%
Net profit
$1.9M
Profit YoY
+34.2%
EPS
$0.21
Net margin
18.7%

Key statistics

Market cap
$101.4M
Forward P/E
0.0
P/B
3.48
Book value
$3.22
EPS (TTM)
$-0.07
52-week high
$12.10
52-week low
$4.52
50-day MA
$10.34
200-day MA
$7.49
Beta
0.57

Analyst view

Analysts rate ImmuCell Corporation a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $14.00.

Shareholding

Insiders
32.13%
Institutions
21.63%

Largest institutional holders

FundStake
Vanguard Capital Management, LLC2.88%
Morgan Stanley - Brokerage Accounts2.45%
Renaissance Technologies Corp1.68%
Cresset Asset Management, LLC1.50%
Bleichroeder LP1.12%
Geode Capital Management, LLC0.73%
Dimensional Fund Advisors, Inc.0.62%
Steadtrust LLC0.50%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for ImmuCell Corporation — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.